序号 |
标题 |
次数 |
作者 |
发布时间 |
71461 |
DOTAGlu-C(AGADPL)2,250612-06-7,多肽,DOTA-RGD探针二聚体 |
94 |
kx |
2024-12-24 |
71462 |
sulfo-SPDB,1193111-39-5,抗体- 药物偶联物 |
70 |
hyy |
2024-12-24 |
71463 |
H2N-PEG8-OH cas:352439-37-3 氨基-八聚乙二醇-羟基 |
78 |
zyl |
2024-12-24 |
71464 |
α,α,α,β-四-[邻(叔丁氧羰丙氨酸)氨基苯基]卟啉H2T(o-BocAla)APP |
156 |
WYQ |
2024-12-24 |
71465 |
HS-PEG8-CH2CH2COOH cas:866889-02-3 巯基-八聚乙二醇-丙酸 |
102 |
zyl |
2024-12-24 |
71466 |
DOTA-PEG-CRGD,大环化合物 |
114 |
kx |
2024-12-24 |
71467 |
NO2-SPDB-sulfo CAS:663598-89-8 |
106 |
h |
2024-12-24 |
71468 |
DOTAP:DOPC:Chol:PEG2000-ATP Liposome (PEGylated),DOTAP:DOPC:Chol:PEG2000-ATP脂质体(聚乙二醇化) |
103 |
axc |
2024-12-24 |
71469 |
Py-ds-dmBut-amido-PEG4-NHS ester |
104 |
h |
2024-12-24 |
71470 |
HO-PEG6-CH2CH2COOH 羟基-六聚乙二醇-丙酸 |
101 |
zyl |
2024-12-24 |
71471 |
Ald-Ph-amido-PEG2 CAS:1061569-06-9 |
67 |
h |
2024-12-24 |
71472 |
DOTA-E-[c(RGDfK)]2,大环化合物 |
70 |
kx |
2024-12-24 |
71473 |
mPEG11-CH2CH2COOtBu的介绍 |
91 |
zyl |
2024-12-24 |
71474 |
Boc-Val-Ala-PAB-PNP CAS:1884578-00-0 |
84 |
h |
2024-12-24 |
71475 |
5,10,15,20-四(4-月桂酰氨基苯基)卟啉(TLAPP) |
111 |
|
2024-12-24 |
71476 |
Amino-PEG8-Boc CAS:756526-06-4 |
98 |
h |
2024-12-24 |
71477 |
DOTAP:Chol:PEG2000-ATP Liposome (PEGylated),DOTAP:Chol:PEG2000-ATP脂质体(聚乙二醇化) |
89 |
axc |
2024-12-24 |
71478 |
Ga-DOTA-FAPI/ANCP-PSMA,大环化合物 |
111 |
kx |
2024-12-24 |
71479 |
5,10,15,20-四(4-甲氧羰基苯基)卟啉(TCMPP) |
113 |
WYQ |
2024-12-24 |
71480 |
N3-PEG4-C2-Pfp ester CAS:1353012-00-6 |
74 |
h |
2024-12-24 |
71481 |
mPEG40-OH cas:1346556-95-3 甲氧基四十聚乙二醇-羟基 |
81 |
zyl |
2024-12-24 |
71482 |
PC:Chol:PEG2000-ATP Liposome (PEGylated),PC:Chol:PEG2000-ATP脂质体(聚乙二醇化) |
122 |
axc |
2024-12-24 |
71483 |
perfluorophenyl 4-(pyridin-2-yldisulfanyl)butanoate ,PDB-PFP,2088570-81-2,ADC试剂 |
80 |
hyy |
2024-12-24 |
71484 |
Ald-Ph-amido-PEG3-C1-Boc CAS:1007215-94-2 |
67 |
h |
2024-12-24 |
71485 |
2 5 8 11-Tetraoxaheptadecane-17-thiol cas:205490-80-8 |
118 |
zyl |
2024-12-24 |
71486 |
72573-82-1,Gd-DOTA,钆特酸,大环化合物 |
95 |
kx |
2024-12-24 |
71487 |
PS:PC:Chol:PEG2000-ATP Liposome (PEGylated),PS:PC:Chol:PEG2000-ATP脂质体(聚乙二醇化) |
147 |
axc |
2024-12-24 |
71488 |
mPEG45-SSG的结构式 |
96 |
zyl |
2024-12-24 |
71489 |
DOTA satoreotide,大环化合物 |
83 |
kx |
2024-12-24 |
71490 |
PS:PC:Chol:PEG2000-ATP Liposome (PEGylated),PS:PC:Chol:PEG2000-ATP脂质体(聚乙二醇化) |
149 |
axc |
2024-12-24 |
71491 |
mPEG62-OH 甲氧基六二聚乙二醇-羟基 |
116 |
zyl |
2024-12-24 |
71492 |
DOTA-甲基四嗪,1610950-41-8,DOTA-多肽分子探针 |
66 |
kx |
2024-12-24 |
71493 |
mPEG45-OH 甲氧基四十五聚乙二醇-羟基 |
106 |
zyl |
2024-12-24 |
71494 |
DOPG:DOPC:Chol:PEG2000-ATP Liposome (PEGylated),DOPG:DOPC:胆固醇:聚乙二醇2000-ATP脂质体(聚乙二醇化) |
163 |
axc |
2024-12-24 |
71495 |
2,5-Dioxo-1-(4-(pyridin-2-yldisulfanyl)butanoyloxy)pyrrolidine-3-sulfonic acid,SPDB-sulfo,1628113-16-5,抗体- 药物偶联物 |
69 |
hyy |
2024-12-24 |
71496 |
5-(4-羧基苯基)-10,15,20-四苯基镁卟啉(MgTPPCOOH) |
84 |
WYQ |
2024-12-24 |
71497 |
mPEG1-OCH2CH2COONHS Ester cas:1127247-34-0 |
80 |
zyl |
2024-12-24 |
71498 |
1610950-41-8,DOTA-MeTz,DOTA-甲基四嗪,大环化合物 |
91 |
kx |
2024-12-24 |
71499 |
橙红色固体5,15-二(4-乙炔基苯基)-10,20-二苯基钴卟啉(CoDETPP) |
96 |
WYQ |
2024-12-24 |
71500 |
原卟啉二甲酯钴配合物PPDMECo |
79 |
WYQ |
2024-12-24 |
71501 |
DOPG:胆固醇:聚乙二醇2000-ATP脂质体(聚乙二醇化),DOPG:Chol:PEG2000-ATP Liposome (PEGylated) |
134 |
axc |
2024-12-24 |
71502 |
mPEG15-OCH2CH2COOH的介绍 |
84 |
zyl |
2024-12-24 |
71503 |
127985-74-4,(p-SCN-Bn)-dota,2-[(4-异硫氰基苯基)甲基]-1,4,7,10-四氮杂环十二烷-1,4,7,10-四乙酸,大环化合物 |
75 |
kx |
2024-12-24 |
71504 |
N-Succinimidyl 4-(2-pyridyldithio)butanoate,SPDB,115088-06-7,ADC试剂 |
94 |
hyy |
2024-12-24 |
71505 |
对照阿仑膦酸盐脂质体(阴离子),Control Alendronate Liposome (Anionic) |
128 |
axc |
2024-12-24 |